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Genome-wide Association Study Identifies Eight Risk Loci and Implicates 335 
Metabo-Psychiatric Origins for Anorexia Nervosa 336 
 337 
Characterized primarily by low BMI, anorexia nervosa is a complex and serious illness1, 338 
affecting 0.9-4% of women and 0.3% of men2-4, with twin-based heritability estimates of 339 
50-60%5. Mortality rates are higher than other psychiatric disorders6, and outcomes are 340 
unacceptably poor7. Combining data from the Anorexia Nervosa Genetics Initiative 341 
(ANGI)8,9 and the Eating Disorders Working Group of the Psychiatric Genomics 342 
Consortium (PGC-ED), we conducted a genome-wide association study (GWAS) of 16,992 343 
anorexia nervosa cases and 55,525 controls, identifying eight significant loci. The genetic 344 
architecture of anorexia nervosa mirrors its clinical presentation showing significant 345 
genetic correlations with psychiatric disorders, physical activity, metabolic (including 346 
glycemic), lipid, and anthropometric traits, independent of the effects of common variants 347 
associated with BMI. Results further encourage a reconceptualization of anorexia nervosa 348 
as a metabo-psychiatric disorder. Explicating the metabolic component is a critical 349 
direction, and attention to both psychiatric and metabolic components may be key to 350 
improving outcomes. 351 
The first PGC-ED GWAS (3,495 cases, 10,982 controls) estimated the common genetic 352 
variant-based heritability of anorexia nervosa as ~20%, identified the first genome-wide 353 
significant locus, and reported significant genetic correlations (rg) between anorexia nervosa and 354 
psychiatric and metabolic/anthropometric phenotypes10. These rg pointed toward metabolic 355 
etiological factors, as they are robust to reverse causation although they could be mediated 356 
associations11 or reflect confounding processes12. To advance genomic discovery in anorexia 357 
10 
nervosa and further explore genetic correlations, we combined samples from ANGI8,9, the 358 
Genetic Consortium for Anorexia Nervosa (GCAN)/Wellcome Trust Case Control Consortium-3 359 
(WTCCC-3)13, and the UK Biobank14, quadrupling our sample size. 360 
Our GWAS meta-analysis included 33 datasets comprising 16,992 cases and 55,525 361 
controls of European ancestry from 17 countries (Supplementary Tables 1-4). We had 80% 362 
power to detect an odds ratio (OR) of 1.09-1.19 (additive model, 0.9% lifetime risk, α = 5 × 10-8, 363 
MAF 0.05–0.5). Typical of complex trait GWAS, we observed test statistic inflation (λ = 1.22) 364 
consistent with polygenicity, with no evidence of significant population stratification according 365 
to the LD intercept and attenuation ratio (Supplementary Results; Supplementary Fig. 1). 366 
Meta-analysis results were completed for autosomes and the X chromosome. We identified eight 367 
loci exceeding genome-wide significance (P < 5 × 10-8; Table 1 for loci; Fig. 1 for the 368 
Manhattan plot; Supplementary Figs. 2a-h and 3a-h for the forest and region plots). Many were 369 
near the threshold for significance, and no significant heterogeneity of SNP associations across 370 
cohorts was detected (P = 0.15-0.64; Supplementary Figs 2a-h). Conditional and joint analysis 371 
(GCTA-COJO)15 confirmed independence of the lead SNPs within the significant loci 372 
(Supplementary Table 5). The eight loci were annotated to identify known protein-coding 373 
genes (Supplementary Table 6; Supplementary Table 7 reports a gene look-up restricted to 374 
the single-gene loci). The previously reported PGC-ED genome-wide significant variant 375 
(rs4622308)10 on 12q13.2 did not reach genome-wide significance (P = 7.02 × 10-5); however, 376 
between-cohort heterogeneity was apparent (I2 = 53.7; Supplementary Fig. 4 and 377 
Supplementary Results). The OR was in the same direction in 22 (67%) of the cohorts (z = 378 
2.00, P = 0.05, 2-tailed). 379 
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Although GWAS findings are informative genome-wide, identifying strong hypotheses 380 
about their connections to specific genes is not straightforward. We evaluated three ways to 381 
“connect” anorexia nervosa GWAS loci to genes: regulatory chromatin interactions; relationship 382 
to brain expression QTLs (eQTLs; using a superset of CommonMind16 and GTEx17) and the 383 
standard approach of gene location within a GWAS locus. The significant anorexia nervosa loci 384 
implicated 121 brain-expressed genes, 74% by location, 55% by adult brain eQTL, 93% by 385 
regulatory chromatin interaction, and 58 genes by all three methods. Supplementary Figs. 5a-h 386 
show the eight GWAS loci, GENCODE gene models, adult brain regulatory chromatin 387 
interactions, brain eQTLs, and functional genomic annotations. 388 
Four single-gene loci were confirmed by eQTL, chromatin interaction, or both. These 389 
were the locus-intersecting genes CADM1 (locus 2 chr11:114.9-115.4 Mb, Supplementary Fig. 390 
5b), MGMT (locus 4, chr10:131.2-131.4 Mb, Supplementary Fig. 5d), FOXP1 (locus 5, 391 
chr3:70.6-71.0 Mb, Supplementary Fig. 5e) and PTBP2 (locus 6, chr1:96.6-97.2 Mb, 392 
Supplementary Fig. 5f). For locus 5, eQTL data implicated a distal gene, GPR27. One 393 
intergenic locus (locus 7, chr5:24.9-25.3 Mb, Supplementary Fig. 5g) had no eQTL or 394 
chromatin interactions whereas the other intergenic locus (locus 8, chr3:93.9-95.0 Mb, 395 
Supplementary Fig. 5h) had eQTL connections to PROS1 and ARL13B. Two complex 396 
multigenic loci had many brain-expressed genes and dense chromatin and eQTL interactions that 397 
precluded identification of any single gene (locus 1, chr3:47.5-51.3 Mb; locus 3, chr2:53.8-54.3 398 
Mb, Supplementary Figs. 5a and 5c). The clearest evidence and connections were for the 399 
single-gene loci intersecting CADM1, MGMT, FOXP1, and PTBP2 and we conclude these genes 400 
may play a role in anorexia nervosa etiology (Supplementary Results). 401 
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Supplementary Table 8 presents multi-trait analysis (GCTA-mtCOJO18 conditioning 402 
our genome-wide significant SNPs on associated variants in GWAS of BMI, type 2 diabetes, 403 
education years, HDL cholesterol, neuroticism, and schizophrenia. Seven loci appear to be 404 
independent. Locus 2 on chr11 may not be unique to anorexia nervosa and may be driven by 405 
genetic variation also associated with type 2 diabetes. 406 
Liability-scale SNP heritability (SNP-h2) was estimated with LD score regression 407 
(LDSC)19,20. Assuming a lifetime prevalence of 0.9-4%2-4, SNP-h2 was 11-17% (s.e. = 1%), 408 
supporting the polygenic nature of anorexia nervosa. Polygenic risk score (PRS) analyses using a 409 
leave-one-out approach indicated that the PRS captures ~1.7% of the phenotypic variance on the 410 
liability scale for discovery P = 0.5. We did not observe differences in polygenic architecture 411 
between anorexia nervosa subtypes with binge eating (2,381 cases, 10,249 controls) or without 412 
(2,262 cases, 10,254 controls) or between males (447 cases, 20,347 controls) and females 413 
(14,898 cases, 27,545 controls) (Methods, Supplementary Results, Supplementary Fig. 6, 414 
Supplementary Table 9). Similar to females, males in the highest PRS decile had 4.13 (95% CI: 415 
2.58-6.62) times the odds of anorexia nervosa than those in the lowest decile. Confirmation of 416 
these results requires larger samples. 417 
We tested SNP-based genetic correlations (SNP-rg) with external traits using bivariate 418 
LDSC19,20. Bonferroni-significant SNP-rg assorted into five trait categories: psychiatric and 419 
personality; physical activity; anthropometric; metabolic; and educational attainment 420 
(Supplementary Table 10). Fig. 2 presents Bonferroni-corrected positive SNP-rg with OCD 421 
(SNP-rg ± s.e. = 0.45 ± 0.08; P = 4.97 × 10-9), MDD (0.28 ± 0.07; P = 8.95 × 10-5), anxiety 422 
disorders (0.25 ± 0.05; P = 8.90 × 10-8), and schizophrenia (0.25 ± 0.03; P = 4.61 × 10-18). This 423 
pattern reflects observed comorbidities in clinical and epidemiological studies21,22. The newly-424 
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identified positive SNP-rg with physical activity (0.17 ± 0.05; P = 1.00 × 10-4) encourages 425 
further exploration of the refractory symptom of pathologically elevated activity in anorexia 426 
nervosa23. We note that the significant SNP-rg of anorexia nervosa with educational attainment 427 
(0.25 ± 0.03; P = 1.69 × 10-15) and related constructs was not seen for IQ24.  428 
Expanding our previous observations10, we present a palette of metabolic and 429 
anthropometric rg with anorexia nervosa more pronounced than in other psychiatric disorders. 430 
We observed significant negative SNP-rg with fat mass (-0.33 ± 0.03; P = 7.23 × 10-25), fat-free 431 
mass (-0.12 ± 0.03; P = 4.65 × 10-5), BMI (-0.32 ± 0.03; P = 8.93 × 10-25), obesity (-0.22 ± 0.03; 432 
P = 2.96 × 10-11), type 2 diabetes (-0.22 ± 0.05; P = 3.82 × 10-5), fasting insulin (-0.24 ± 0.06; P 433 
= 2.31 × 10-5), insulin resistance (-0.29 ± 0.07; P = 2.83 × 10-5), and leptin (-0.26 ± 0.06; P = 434 
4.98 × 10-5), and a significant positive SNP-rg with HDL cholesterol (0.21 ± 0.04; P = 3.08 × 10-435 
7). 436 
Systems biology analyses of our results revealed preliminarily interesting results 437 
(Methods, Supplementary Tables 11-13, Supplementary Figs. 7-15). Gene-wise analysis with 438 
MAGMA prioritized 79 Bonferroni-significant genes, most within the multigenic locus on chr3 439 
(Supplementary Table 11). MAGMA indicated an association with NCAM1  (Supplementary 440 
Table 11) the expression of which increases in response to food restriction in a rodent activity-441 
based anorexia nervosa model25. Partitioned heritability analysis showed, as with other GWAS26, 442 
considerable enrichment of SNP-h2 in conserved regions (fold enrichment = 24.97, s.e. = 3.29, P 443 
= 3.32 × 10-11; Supplementary Fig. 7)27. Cell type group-specific annotations revealed that the 444 
overall SNP-h2 is significantly enriched for CNS tissue (Supplementary Fig. 8). One biological 445 
pathway was significant: GO:positive_regulation_of_embryonic_development (32 genes, P = 446 
1.39 × 10-7; Supplementary Table 12), which contains two Bonferroni-significant genes on 447 
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chr3, CTNNB1 and DAG1. CTNNB1 encodes catenin beta-1, which is part of adherens junctions, 448 
and DAG1 encodes dystroglycan, a receptor which binds extracellular matrix proteins28. DAG1 449 
falls within locus 1 (47.5-51.3 Mb). This pathway points to a potential role of developmental 450 
processes in the etiology of this complex phenotype (although this is currently speculative). 451 
Genes associated with anorexia nervosa were enriched for expression in most brain tissues, 452 
particularly the cerebellum, which has a notably high proportion of neurons29 (Supplementary 453 
Fig. 9). Among 24 brain cell types from mouse brain, significant enrichment was found for 454 
medium spiny neurons and pyramidal neurons from hippocampal CA1 (Supplementary Fig. 455 
10). Both medium spiny and pyramidal neurons are linked to feeding behaviors including food 456 
motivation and reward30,31 (Supplementary Results). Using PrediXcan (Supplementary 457 
Methods), 36 genes were predicted to be differentially expressed in GTEx tissues or blood 458 
(Supplementary Table 13) with the expression of MGMT predicted to be downregulated in the 459 
caudate. We cautiously note that these results represent the first indications of specific pathways, 460 
tissues, and cell types that may mediate genetic risk for anorexia nervosa. 461 
Because low BMI is pathognomonic of anorexia nervosa, we investigated the extent to 462 
which genetic variants associated with BMI accounted for genetic correlations with metabolic 463 
and anthropometric traits. First, covarying for the genetic associations of BMI (Methods) led to 464 
a mild but statistically non-significant attenuation of the SNP-rg between anorexia nervosa and 465 
fasting insulin, leptin, insulin resistance, type 2 diabetes, and HDL cholesterol (Supplementary 466 
Tables 14-15), suggesting that anorexia nervosa shares genetic variation with these metabolic 467 
phenotypes that may be independent of BMI. Second, we investigated bidirectional causality 468 
using generalized summary data-based Mendelian randomization18. GSMR analyses indicate a 469 
significant bidirectional causal relationship such that anorexia nervosa risk-increasing alleles 470 
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may increase risk for low BMI and BMI-lowering alleles may increase the risk of anorexia 471 
nervosa (Supplementary Table 16). It is important to note that having only eight genome-wide 472 
significant loci for anorexia nervosa render this analysis marginally powered in the direction of 473 
anorexia nervosa to BMI, although this analysis is well powered in the direction of BMI to 474 
anorexia nervosa. 475 
Replication is challenging with GWAS of low prevalence conditions like anorexia 476 
nervosa, as replication samples must be sufficiently powered to detect the initial findings. We 477 
included all available samples in our analysis to maximize chances of reaching the GWAS 478 
inflection point, after which there might be a linear increase in “hits”32. The PRS leave-one-out 479 
analyses provide evidence of replication by demonstrating a higher burden of anorexia nervosa 480 
common risk variants in cases, compared with controls, across all the cohorts (Supplementary 481 
Fig. 16). 482 
 In conclusion, we report multiple genetic loci alongside promising clinical and functional 483 
analyses and enrichments. The increased sample size in the present GWAS has allowed us to 484 
characterize more fully the metabolic contribution to anorexia nervosa than our previous report10 485 
by revealing significant rg with metabolism related phenotypes including glycemic and 486 
anthropometric traits and by demonstrating that the effect is robust to correction for the effects of 487 
common variants significantly associated with BMI. Low BMI has traditionally been viewed as a 488 
consequence of the psychological features of anorexia nervosa (i.e., drive for thinness and body 489 
dissatisfaction). This perspective has failed to yield interventions that reliably lead to sustained 490 
weight gain and psychological recovery7. Fundamental metabolic dysregulation may contribute 491 
to the exceptional difficulty that individuals with anorexia nervosa have in maintaining a healthy 492 
BMI (even after therapeutic renourishment). Our results encourage consideration of both 493 
16 
metabolic and psychological drivers of anorexia nervosa when exploring new avenues for 494 
treating this frequently lethal illness.  495 
URLs. GCTA, http://cnsgenomics.com/software/gcta; GSMR, 496 
http://cnsgenomics.com/software/gsmr; LDSC, https://github.com/bulik/ldsc; MAGMA, 497 
http://ctg.cncr.nl/software/magma. 498 
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 667 
Figure Titles and Captions 668 
 669 
Figure 1. The Manhattan plot for the primary genome-wide association meta-analysis of 670 
anorexia nervosa with 33 case-control samples (16,992 cases and 55,525 controls of 671 
European descent). The -log10(P) values for the association tests (two-tailed) are shown on the 672 
y-axis and the chromosomes are ordered on the x-axis. Eight genetic loci surpassed genome-wide 673 
significance (-log10(P) > 7.3). The lead variant is indicated by a diamond and green circles show 674 
the variants in linkage-disequilibrium. The blue and red colors differentiate adjacent 675 
chromosomes. 676 
 677 
Figure. 2. Bonferroni-significant genetic correlations (SNP-rgs) and standard errors (error 678 
bars) between anorexia nervosa and other phenotypes as estimated by LD score regression. 679 
Only traits with significant P values following Bonferroni correction are shown. Correlations 680 
with 447 phenotypes were tested (Bonferroni-corrected significance threshold P > 1.11 x 10-4).  681 
Complete results are shown in Table S10. PGC = Psychiatric Genomics Consortium, UKB = UK 682 
Biobank, HOMA-IR = Homeostatic model assessment - insulin resistance. 683 
1 
Table 1. Newly associated genome-wide significant loci for anorexia nervosa 
Locus Chr Basepair region Lead SNP BP P A1/A2 OR s.e. Freq Type Number 
of genes 
Nearest gene 
range left range right 
1 3 47588253 51368253 rs9821797 48718253 6.99E-15 A/T 1.17 0.02 0.12 multigenic 111 NCKIPSD 
2 11 114997256 115424956 rs6589488 115096956 6.31E-11 A/T 1.14 0.02 0.13 single-gene 1 CADM1 
3 2 53881813 54362813 rs2287348 54039813 5.62E-09 T/C 1.11 0.02 0.16 multigenic 13 ASB3, ERLEC1 
4 10 131269764 131463964 rs2008387 131448764 1.73E-08 A/G 1.08 0.01 0.33 single-gene 2 MGMT 
5 3 70670750 71074150 rs9874207 71019750 2.05E-08 C/T 1.08 0.01 0.49 single-gene 2 FOXP1 
6 1 96699455 97284455 rs10747478 96901455 3.13E-08 T/G 1.08 0.01 0.41 single-gene 2 PTBP2 
7 5 24945845 25372845 rs370838138 25081845 3.17E-08 G/C 1.08 0.01 0.56 intergenic 0 CDH10 
8 3 93968107 95059107 rs13100344 94605107 4.21E-08 T/A 1.08 0.01 0.54 intergenic 2 NSUN3 
Note. Shown are the results of the GWAS meta-analysis of anorexia nervosa (16,992 cases and 55,552 controls) which detected eight genome-wide significant 
loci. All of the eight loci are novel. Chr (chromosome) and Region (hg19) are shown for SNPs with P < 1e-05 and linkage-disequilibrium (LD) r2 > 0.1 with the 
most associated "lead" SNP, the location of which is given in BP (basepair). A1/A2 refers to Allele 1/Allele 2 and OR and s.e. are the odds ratio and standard 
error for the association between A1 and the phenotype. Freq is the frequency of A1 in controls. Number of genes was determined by genomic location, adult 
brain eQTL, regulatory chromatin interactions, and MAGMA gene-wise analysis (see Methods). Nearest gene is the nearest gene within the region of LD 
"friends" of the lead variant (LD-r2 > 0.6 +/- 500 Kb). The meta-analysis was restricted to variants with minor allele frequency (MAF) ≥ 0.01 and information 
quality (INFO) score ≥ 0.70. All loci were confirmed via forest plots based on consistent direction of effect in the majority of cohorts and via region plots 
whereby neighboring LD "friends" were required to show a similar effect. Chromosome X was analyzed but had no loci that reached genome-wide significance. 
Note that although lead variants are annotated to the nearest gene, this does not mean that the gene listed is a causal gene. 
1 
Methods 684 
Samples and study design. Thirty-three datasets with 16,992 anorexia nervosa cases and 55,525 685 
controls were included in the primary GWAS. We included individuals from the Eating 686 
Disorders Working Group of the Psychiatric Genomics Consortium (PGC-ED) Freeze 110; newly 687 
collected samples from the Anorexia Nervosa Genetics Initiative (ANGI)8,9; archived samples 688 
from the Genetic Consortium for Anorexia Nervosa (GCAN)/Wellcome Trust Case Control 689 
Consortium-3 (WTCCC3)13; anorexia nervosa samples from UK Biobank14; and additional 690 
controls from Poland. Case definitions established a lifetime diagnosis of anorexia nervosa via 691 
hospital or register records, structured clinical interviews, or on-line questionnaires based on 692 
standardized criteria (DSM-III-R, DSM-IV, ICD-8, ICD-9, or ICD-10), whereas in the UK 693 
Biobank cases self-reported a diagnosis of anorexia nervosa. Controls were carefully matched for 694 
ancestry, and some, but not all control cohorts were screened for lifetime eating and/or some or 695 
all psychiatric disorders. Given the relative rarity of anorexia nervosa, large unscreened control 696 
cohorts were deemed appropriate for inclusion33.  697 
The cohorts are detailed in the Supplement. Ethical approvals and consent forms were 698 
reviewed and archived for all participating cohorts (see Supplementary Methods ANGI-DK for 699 
Danish methods). Summary details about ascertainment (Supplementary Table 2), the 700 
genotyping platforms used (Supplementary Table 3), and genotype availability (Supplementary 701 
Table 4) can be accessed in the Supplement.  702 
 703 
Statistical analysis. Data processing and analysis were done on the Lisa Compute Cluster hosted 704 
by SURFsara (http://www.surfsara.nl) and the GenomeDK high-performance computing cluster 705 
(http://genome.au.dk).  706 
2 
Meta-analysis of genome-wide association data. Quality control (QC), imputation, GWAS, and 707 
meta-analysis followed the standardized pipeline of the PGC, Ricopili (Rapid Imputation 708 
Consortium Pipeline). Ricopili versions used were 2017_Oct_11.002 and 2017_Nov_30.003. QC 709 
included SNP and sample QC, population stratification and ancestry outliers, and familial and 710 
cryptic relatedness. Further information about the Ricopili pipeline is available from the website 711 
(https://sites.google.com/a/broadinstitute.org/ricopili) and GitHub repository 712 
(https://github.com/Nealelab/ricopili/tree/master/rp_bin). Further details of the QC procedures 713 
can be found in the Supplementary Methods.  714 
 715 
Imputation. Imputation of SNPs and insertions-deletions was based on the 1000 Genomes Phase 716 
3 (http://www.internationalgenome.org) data34.  717 
 718 
GWAS. GWASs were conducted separately for each cohort using imputed variant dosages and an 719 
additive model. Covariates nominally associated with the phenotype in univariate analysis (P < 720 
0.05) and five ancestry PCs were included in GWAS (Supplementary Table 18). These analyses 721 
used the tests and methods programmed in the Ricopili pipeline. Genomic inflation factors (λ) of 722 
the final datasets indicated no evidence of inflation of the test statistics due to population 723 
stratification or other sources (Supplementary Table 1). The 33 cohorts were meta-analyzed with 724 
the Ricopili pipeline which uses an inverse-variance weighted fixed-effect model. We filtered 725 
our GWAS results with minor allele frequency (MAF) ≥ 0.01 and INFO score ≥ 0.70 (indicating 726 
“high-quality”).  727 
 728 
3 
Analysis of chrX. Several cohorts in the primary GWAS did not have X chromosome variant 729 
data, specifically, some GCAN-based cohorts (fre1, ukd1, usa1, gns2) and were excluded. 730 
Imputation was performed separately from the autosome35. ChrX variants in the 731 
pseudoautosomal regions were excluded prior to imputation. SNPs exceeding MAF and INFO 732 
score thresholds of 0.01 and 0.70 were retained and analysis was performed with PLINK v1.9 733 
(https://www.cog-genomics.org/plink2) and Ricopili.  734 
 735 
Female-only GWAS. A supplementary GWAS analysis was conducted on females only to 736 
determine the similarity of the results to the primary GWAS analysis which included both 737 
females and males. The cohorts that did not have chrX variants to verify sex could not be 738 
included (fre1, ukd1, usa1, gns2). 739 
 740 
Distance- and LD-based clumping. The GWAS results implicate genomic regions (“loci”). To 741 
define a locus, (1) SNPs that met the genome-wide significant threshold of P < 5 × 10-8 were 742 
identified; (2) clumping was used to convert significant SNPs to regions. The SNP with the 743 
smallest P value in a genomic window was kept as the index SNP and SNPs in high linkage 744 
disequilibrium (LD) with the index SNP defined the left and right end of the region (SNPs with 745 
P < 0.0001 and r 2 > 0.1 within 3 Mb windows); (3) partially or wholly overlapping clumps 746 
within 50 Kb were identified and merged into one region; (4) only loci with additional evidence 747 
of association from variants in high LD as depicted by regional plots were retained; further, 748 
forest plots needed to confirm the associations based on the majority of cohorts; and (5) 749 
conditional analyses were conducted to identify SNPs with associations independent of the top 750 
SNP within the genomic chunk of interest.  751 
4 
 752 
Annotation. Genome-wide significant loci were annotated with RegionAnnotator 753 
(https://github.com/ivankosmos/RegionAnnotator) to identify known protein-coding genes 754 
within loci (Supplementary Table 6).  755 
 756 
Conditional and joint analysis. Conditional and joint analysis was conducted using GCTA-757 
COJO15. GCTA-COJO investigates every locus with a joint combination of independent markers 758 
via a genome-wide SNP selection procedure. It takes into account the LD correlations between 759 
SNPs and runs a conditional and joint analysis on the basis of conditional P values. After a 760 
model optimizing process, the joint effects of all selected SNPs are calculated. The largest 761 
subsample from our GWAS (sedk) was used to approximate the underlying LD structure of the 762 
investigated lead SNPs. The conditional regression was performed in a stepwise manner using 763 
the GCTA software36. We analyzed SNPs that had a P < 5 × 10-8 (Supplementary Table 5).  764 
 765 
Multi-trait-based conditional and joint analysis. To separate marginal effects from conditional 766 
effects (i.e., the effect of a risk factor on an outcome controlling for the effect of another risk 767 
factor), we performed a multi-trait-based conditional and joint analysis (GCTA-mtCOJO)18 using 768 
an extension of the GCTA software36 (Supplementary Table 8). This method uses summary-level 769 
data to perform the conditional analysis. We conditioned the results of our anorexia nervosa 770 
GWAS on GWAS results for education years37, type 2 diabetes38, HDL cholesterol39, BMI 771 
(Hübel, Gaspar, Coleman, Hanscombe, Purves…Breen, unpublished report), schizophrenia40, 772 
and neuroticism41. We again used the individual-level genotype data from our largest cohort 773 
(sedk) to approximate the underlying LD structure. As a first step, the method performs a 774 
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generalized summary data-based Mendelian randomization (GSMR) analysis to test for causal 775 
association between the outcome (i.e., anorexia nervosa) and the risk factor (e.g., schizophrenia). 776 
We removed potentially pleiotropic SNPs from this analysis by the heterogeneity in dependent 777 
instruments (HEIDI) outlier method18. Pleiotropy is the phenomenon when a single locus directly 778 
affects several phenotypes. The power of the HEIDI-outlier method is dependent on sample size 779 
of the GWAS. Pleiotropic SNPs are defined as the SNPs that show an effect on the outcome that 780 
significantly diverges from that expected under a causal model. Second, the GCTA-mtCOJO 781 
method calculates the genetic correlation between the exposure and the outcome using linkage 782 
disequilibrium score regression (LDSC) to adjust for genetic overlap19,20. It also uses the 783 
intercept of the bivariate LDSC to account for potential sample overlap19,20. As a result, GCTA-784 
mtCOJO calculates conditional betas, conditional standard errors, and conditional P values. 785 
Subsequently, we clumped the conditional GWAS results using the standard PLINK v1.942 786 
algorithm (SNPs with P < 0.0001 and r2 > 0.1 within 3 Mb windows) to investigate if any of the 787 
genome-wide significant loci showed dependency on genetic variation associated with other 788 
phenotypes. As stated in Zhu et al.18, the GCTA-mtCOJO analysis requires the estimates of bxy 789 
of the covariate risk factors on the target risk factor and disease, rg of the covariate risk factors, 790 
heritability (h2snp) for the covariate risk factors, and the sampling covariance between SNP 791 
effects estimated from potentially overlapping samples.  792 
 793 
eQTL and Hi-C interactions. Although GWAS findings are informative genome-wide, 794 
identifying strong hypotheses about their connections to specific genes is not straightforward. 795 
The lack of direct connections to genes constrains subsequent experimental modeling and efforts 796 
to develop improved therapeutics. Genomic location is often used to connect significant SNPs to 797 
6 
genes, but this is problematic because GWAS loci usually contain many correlated and highly 798 
significant SNP associations over hundreds of Kb. Moreover, the three-dimensional (3D) 799 
arrangement of chromosomes in cell nuclei enables regulatory interactions between genomic 800 
regions located far apart43. Chromosome conformation capture methods like Hi-C enable 801 
identification of 3D interactions in vivo44,45 and can clarify GWAS findings. For example, an 802 
intergenic region associated with multiple cancers was shown to be an enhancer for MYC via a 803 
long-range chromatin loop46,47, and intronic FTO variants are robustly associated with body mass 804 
but influence expression of distal genes via long-range interactions48. The Nature paper of Won 805 
et al.49 used Hi-C to assess the 3D chromatin interactome in fetal brain, and asserted connections 806 
of some schizophrenia associations to specific genes.  807 
To gain further understanding of 3D chromatin organization of the brain and to evaluate 808 
disease relevance, we applied “easy Hi-C”50 to postmortem samples (N = 3 adult temporal 809 
cortex). Library quality and yield from eHi-C are comparable to conventional Hi-C but requires 810 
much less starting material. Please refer to the following pre-print for details on methodology, 811 
data processing, quality control and statistical models used for these analyses51. We generated 812 
sufficient reads to enable a kilobase resolution map of the chromatin interactome from adult 813 
human brain. To our knowledge, these are the deepest Hi-C data on any human tissue (excluding 814 
cell lines) as they generated 22.5X as many cis-contacts as for the next largest datasets (DLPFC 815 
and hippocampus). We generated tissue RNA-seq, total-stranded RNA-seq, ChIP-seq (H3K27ac, 816 
H3K4me3, and CTCF), and open chromatin data (ATAC-seq) for adult brain to help interpret the 817 
eHi-C results. We also integrated brain expression and eQTL data from GTEx to aid these 818 
analyses. The Hi-C analysis is unbiased in that all chromatin interactions that pass a confidence 819 
7 
threshold are considered when evaluating the associations between SNPs and genes (i.e., it is not 820 
a capture experiment where only “candidate” SNP-to-gene associations are evaluated). 821 
Similar to the work by Won et al.49, we used Hi-C data generated from human adult brain 822 
to identify genes implicated by three-dimensional functional interactomics (Supplementary Figs. 823 
5 a-h). These Hi-C data (N = 3, anterior temporal cortex) contain more than 103K high-824 
confidence, regulatory chromatin interactions51. These interactions capture the physical 825 
proximity of two regions of the genome in brain nuclei (“anchors”, 10 Kb resolution) although 826 
they are separated by 20 Kb to 2 Mb in genomic distance. We focused on the regulatory subset 827 
of E-P or P-P (E = enhancer, P = promoter) chromatin interactions (with P defined by location of 828 
an open chromatin anchor near the transcription start site of an adult brain-expressed transcript 829 
and E defined by overlap with open chromatin in adult brain plus either H3K27ac or H3K4me3 830 
histone marks). The presence of a regulatory chromatin interaction from a GWAS locus to a gene 831 
provides a strong hypothesis about SNP-to-gene regulatory functional interactions. 832 
 833 
SNP-based heritability estimation. LDSC software (https://github.com/bulik/ldsc) and method 834 
were used to estimate SNP-based heritabilities for each cohort and overall19,20. We used 835 
precomputed LD scores based on the 1000 Genomes Project European ancestry samples34 836 
directly downloaded from https://github.com/bulik/ldsc. The liability scale estimate assumed a 837 
population prevalence of 0.9%-4% for anorexia nervosa2,3.  838 
 839 
Within-trait prediction: polygenic risk scoring. Polygenic leave-one-dataset-out analysis, using 840 
PRSice v2.1.352, was conducted in the first instance to identify any extreme outlying datasets. In 841 
addition, it enabled the evaluation of the association between anorexia nervosa polygenic risk 842 
8 
score (PRS) and anorexia nervosa risk in an independent cohort as a means of replication of the 843 
GWAS results. We derived a PRS for anorexia nervosa from the meta-analysis of all datasets 844 
except for the target cohort, then applied the PRS to the target cohort to predict affected status 845 
(Supplementary Fig. 16). Logistic regression was performed, including as covariates the first five 846 
ancestry components and any other PCs significantly associated with the phenotype in the target 847 
cohort, and the target cohort was split into deciles based on anorexia nervosa PRS, with decile 1 848 
comprised of those with the lowest anorexia nervosa PRS serving as the referent.  849 
 850 
Anorexia nervosa subtype analysis. PRS analyses were conducted with anorexia nervosa 851 
subgroups to investigate prediction of case status across the subtypes. For this, we split the 852 
anorexia nervosa cases to two groups based on whether binge eating was present. First, GWAS 853 
meta-analyses were conducted for (a) anorexia nervosa with binge eating vs controls (2,381 854 
cases and 10,249 controls; k = 3 datasets: aunz, chop, usa2) and (b) anorexia nervosa with no 855 
binge eating vs controls (2,262 cases and 10,254 controls; k = 3 datasets: aunz, chop, usa2). 856 
Controls were randomly split between analyses to maintain independence (Supplementary Fig. 857 
6). Genetic correlation analysis using LDSC19,20 was conducted to examine the potential genetic 858 
overlap of the two anorexia nervosa subtypes (Supplementary Table 9). Second, using PRSice52, 859 
we calculated PRS for each anorexia nervosa subtype separately in the three target cohorts for 860 
which anorexia nervosa subtype data were available. Finally, mean PRS scores were estimated 861 
for each subtype by cohort after accounting for covariates in R. Subtype phenotyping is 862 
described in the Supplementary Methods.  863 
 864 
9 
Males. In order to assess whether sex-specific differences in anorexia nervosa genetic risk load 865 
exist, we calculated PRS, using PRSice52, from a GWAS meta-analysis performed on females 866 
only (14,898 cases and 27,545 controls) and applied it to a male-only target cohort (447 cases 867 
and 20,347 controls) to predict affected status.  868 
 869 
Cross-trait analysis: genetic correlations. Common variant-based genetic correlation (SNP-rg) 870 
measures the extent to which two traits or disorders share common genetic variation. SNP-rg 871 
between anorexia nervosa and 447 traits (422 from an internally curated dataset and 25 from 872 
LDHub53) were tested using GWAS summary statistics via an analytical extension of LDSC19,20. 873 
The sources of the summary statistics files (PMID, DOI, or unpublished results) used in the 874 
LDSC are provided in Supplementary Table 10. When there were multiple summary statistics 875 
files available for a trait, significant SNP-rg reported in the main text were chosen based on the 876 
largest sample size and/or matching ancestry with our sample (i.e., European ancestry). 877 
Genetic correlations with anorexia nervosa corrected for BMI were carried out to 878 
investigate whether the observed genetic correlations between anorexia nervosa and metabolic 879 
phenotypes were attributable to BMI or partially independent. We used GCTA-mtCOJO18 to 880 
perform a GWAS analysis for anorexia nervosa conditioning on BMI using BMI summary data 881 
from our UK Biobank analysis (described in the next section) to derive anorexia nervosa GWAS 882 
summary statistics corrected for  the common variants genetic component of BMI 883 
(Supplementary Tables 14 and 15).  884 
 885 
GWAS of related traits in UK Biobank. Several GWAS analyses were carried out for traits in UK 886 
Biobank to allow us to investigate body composition genetics in healthy individuals without a 887 
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psychiatric disorder, a weight-altering disorder, or who were taking weight-altering medication. 888 
We also used UK Biobank to carry out GWAS of physical activity level, anxiety, and 889 
neuroticism. For details see the Supplementary Methods. 890 
 891 
Generalized summary data-based Mendelian randomization (GSMR). We performed two 892 
bidirectional GSMR analyses18 to test for the causal association between first, BMI and anorexia 893 
nervosa, and second, Type 2 diabetes and anorexia nervosa, using an extension of the GCTA 894 
software36 (Supplementary Table 16). We used the individual-level genotype data from our 895 
largest cohort (sedk) to approximate the underlying LD structure. We removed potentially 896 
pleiotropic SNPs from this analysis by the HEIDI outlier method18. Pleiotropic SNPs are defined 897 
as the SNPs which show an effect on the outcome that significantly diverges from the one 898 
expected under a causal model. The method uses the intercept of the bivariate LD score 899 
regression to account for potential sample overlap19,20. As a rule of thumb GSMR requires 900 
GWAS to have at least ten genome-wide significant hits. We lowered the threshold for this 901 
requirement to eight SNPs in our analyses of anorexia nervosa as an exposure and BMI or Type 902 
2 diabetes as an outcome. Results, therefore, should be interpreted cautiously. We, furthermore, 903 
investigated bidirectional conditional effects between BMI or Type 2 diabetes and anorexia 904 
nervosa. We used GCTA-mtCOJO to perform a GWAS analysis for anorexia nervosa 905 
conditioning on (1) BMI using summary data from our UK Biobank analysis and (2) Type 2 906 
diabetes using summary data38. Our anorexia nervosa GWAS and the BMI and Type 2 diabetes 907 
GWASs are based on independent samples. For BMI, we also re-ran the GSMR analysis using 908 
the BMI-adjusted anorexia nervosa GWAS summary data from the GCTA-mtCOJO analysis.  909 
 910 
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Gene-wise analysis. MAGMA v1.0654 was used to perform a gene-wise test of association with 911 
anorexia nervosa based on GWAS summary statistics. MAGMA generates gene-based P values 912 
by combining SNP-based P values within a gene while accounting for LD. In order to include 913 
regulatory regions, SNPs are mapped to genes within a 35 kb upstream and 10 kb downstream 914 
window, and the gene P value is obtained using the “multi=snp-wise” model, which aggregates 915 
mean and top SNP association models. We tested 19,846 ENSEMBL genes, including the X 916 
chromosome (Supplementary Table 11). As reference panel for the underlying LD structure we 917 
used 1000 Genomes European data phase 334.  918 
 919 
Pathway analysis. MAGMA v1.0654 was used to perform a competitive pathway analysis, testing 920 
whether genes associated with anorexia nervosa were more enriched in a given pathway than all 921 
other pathways. The analysis included chrX. Biological pathways were defined using gene 922 
ontology pathways and canonical pathways from MSigDB v6.155, and psychiatric pathways 923 
mined from the literature. A total 7,268 pathways were tested (Supplementary Table 12).  924 
 925 
Partitioned heritability. Partitioned heritability was investigated using stratified LDSC26 which 926 
estimates the per-SNP contribution to overall SNP-heritability (SNP-h2) across various 927 
functional annotation categories of the genome (Supplementary Fig. 7). It accounts for linked 928 
markers and uses a ‘full baseline model’ of 24 annotations that are not specific to any cell type. 929 
We excluded the MHC region in our analysis. SNP-h2 can be partitioned in two different ways: a 930 
non-cell type-specific and a cell type-specific manner. Partitioned heritability analysis was used 931 
to test for cell type-specific enrichment in the GWAS of anorexia nervosa among 10 cell type 932 
groups; adrenal and pancreas, cardiovascular, central nervous system (CNS), connective and 933 
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bone, gastrointestinal, immune and hematopoietic, kidney, liver, skeletal muscle, and other 934 
tissue, which includes adipose tissue (Supplementary Fig. 8).  935 
 936 
Gene expression. We conducted a series of gene expression analyses as detailed in the 937 
Supplementary Methods.  938 
 939 
Reporting summary 940 
 941 
Further information on research design is available in the Life Science Reporting Summary 942 
linked to this article. 943 
 944 
Data availability 945 
 946 
The Psychiatric Genomics Consortium’s (PGC) policy is to make genome-wide summary results 947 
public. Genome-wide summary statistics for the meta-analysis are freely downloadable from 948 
PGCs download website (http://www.med.unc.edu/pgc/results-and-downloads). Individual-level 949 
data are deposited in dbGaP (http://www.ncbi.nlm.nih.gov/gap) for ANGI-ANZ/SE/US 950 
(accession number phs001541.v1.p1) and CHOP/PFCG (accession number phs000679.v1.p1). 951 
ANGI-DK individual-level data are not available in dbGaP owing to Danish laws, but are 952 
available via collaboration with PIs. GCAN/WTCCC3 individual-level data are deposited in 953 
EGA (https://www.ebi.ac.uk/ega) (accession number EGAS00001000913) with the exception of 954 
Netherlands and US/Canada, which are available via collaboration with PIs. UK Biobank 955 
13 
individual-level data can be applied for on the UK Biobank website 956 
(http://www.ukbiobank.ac.uk/register-apply). 957 
  958 
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Obsessivecompulsive disorder (PGC)
Major depressive disorder (PGC)
Schizophrenia (PGC)
Anxiety (UKB)
Depressive symptoms
Neuroticism (UKB)
Years of education
College completion
Attainment of a college or a university degree
Physical activity (objectively-measured)
HOMA-IR: Insulin resistance (age- & sex-adjusted)
Fasting insulin (age- & sex-adjusted)
Leptin (not BMI-adjusted)
Fasting insulin (BMI-adjusted)
Type 2 diabetes
HDL cholesterol
Body fat percentage (UKB)
Fat mass (UKB)
Body mass index (UKB)
Waist circumference
Overweight (BMI 25-30)
Obesity class 1 (BMI 30-35)
Waist-to-hip ratio
Hip circumference
Extreme body mass index
Obesity class 2 (BMI 35-40)
Waist circumference (BMI-adjusted)
Fatfree mass
-0.25 0.25 0.500.00
Genetic correlation rg
Category
Psychiatric disorder/trait
Personality trait
Educational attainment
Physical activity
Metabolic trait
Anthropometric trait
